Craig MD - Alkermes Plc Executive Officer
| ALKS Stock | USD 24.01 0.53 2.16% |
Executive
Craig MD is Executive Officer of Alkermes Plc
| Age | 56 |
| Address | Connaught House, Dublin, Ireland, D04 C5Y6 |
| Phone | 353 1 772 8000 |
| Web | https://www.alkermes.com |
Alkermes Plc Management Efficiency
The company has return on total asset (ROA) of 0.1281 % which means that it generated a profit of $0.1281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4622 %, meaning that it created $0.4622 on every $100 dollars invested by stockholders. Alkermes Plc's management efficiency ratios could be used to measure how well Alkermes Plc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024. Return On Capital Employed is likely to gain to 0.27 in 2024. At this time, Alkermes Plc's Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 165.2 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chad Gassert | ANI Pharmaceuticals | 48 | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| James Marken | ANI Pharmaceuticals | 61 | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Jeffrey Plumer | Evolus Inc | N/A | |
| Vivek Mittal | Dr Reddys Laboratories | N/A | |
| Ori Gutwerg | ANI Pharmaceuticals | 49 | |
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Ingrid Delaet | Neurocrine Biosciences | 57 | |
| Donn Casale | Dynavax Technologies | N/A | |
| Sauri Gudlavalleti | Dr Reddys Laboratories | 42 | |
| Esq III | Pacira Pharmaceuticals | 50 | |
| Eric Benevich | Neurocrine Biosciences | 59 | |
| Dennis McLoughlin | Pacira Pharmaceuticals | 58 | |
| Daniel Martin | Deciphera Pharmaceuticals LLC | 49 | |
| Christopher OBrien | Neurocrine Biosciences | 59 | |
| Gaozhong Zhu | Eagle Pharmaceuticals | N/A | |
| Dashyant Dhanak | Deciphera Pharmaceuticals LLC | 63 | |
| Jeff Coon | Dynavax Technologies | 61 | |
| Dimitri Grigoriadis | Neurocrine Biosciences | 66 | |
| Jeffrey JD | Deciphera Pharmaceuticals LLC | N/A | |
Management Performance
| Return On Equity | 0.46 | ||||
| Return On Asset | 0.13 |
Alkermes Plc Leadership Team
Elected by the shareholders, the Alkermes Plc's board of directors comprises two types of representatives: Alkermes Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alkermes. The board's role is to monitor Alkermes Plc's management team and ensure that shareholders' interests are well served. Alkermes Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alkermes Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Norman, Senior Relations | ||
| David Gaffin, Senior Vice President Chief Legal Officer | ||
| Richard Pops, Chairman and CEO | ||
| Iain Brown, Chief Accounting Officer | ||
| Craig Hopkinson, Senior Vice President - Clinical Development and Medical Affairs, Chief Medical Officer | ||
| Gordon Pugh, COO, Senior Vice President Chief Risk Officer | ||
| Nancy Snyderman, Director | ||
| Declan OConnor, Health Environment | ||
| James Robinson, COO | ||
| Michael Landine, Senior Vice President - Corporate Development | ||
| Thomas Harvey, Chief IT | ||
| James Frates, CFO, Sr. VP and Treasurer | ||
| Craig MD, Executive Officer | ||
| Floyd MD, Founder | ||
| Nancy Wysenski, Director | ||
| Mark Stejbach, Senior Vice President Chief Commercial Officer | ||
| Shane Cooke, President | ||
| Sandra Coombs, Senior Relations | ||
| Mark Namchuk, Senior Vice President - Research, Pharmaceutical and Non-Clinical Development | ||
| Rebecca Peterson, Senior Vice President | ||
| Floyd Bloom, Independent Director | ||
| Kathryn Biberstein, Chief Compliance Officer, Chief Legal Officer, Sr. VP and Secretary | ||
| Robert Breyer, Independent Director | ||
| Wendy Dixon, Independent Director | ||
| Blair Jackson, Executive Officer | ||
| David Anstice, Independent Director | ||
| Paul Mitchell, Lead Independent Director | ||
| Elliot Ehrich, Senior Vice President - Research and Development, Chief Medical Officer | ||
| Samuel Parisi, Interim Finance | ||
| CTodd Nichols, Senior Vice President of Sales and Marketing | ||
| Stephen Schiavo, Senior Resources |
Alkermes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alkermes Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.46 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.21 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 3.7 B | ||||
| Shares Outstanding | 169.18 M | ||||
| Shares Owned By Insiders | 1.24 % | ||||
| Shares Owned By Institutions | 98.76 % | ||||
| Number Of Shares Shorted | 13.52 M | ||||
| Price To Earning | (38.45) X |
Pair Trading with Alkermes Plc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alkermes Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alkermes Plc will appreciate offsetting losses from the drop in the long position's value.Moving together with Alkermes Stock
| 0.77 | EVOK | Evoke Pharma | PairCorr |
Moving against Alkermes Stock
| 0.67 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
| 0.64 | ELYM | Eliem Therapeutics Trending | PairCorr |
| 0.51 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
| 0.41 | IBIO | Ibio Inc | PairCorr |
The ability to find closely correlated positions to Alkermes Plc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alkermes Plc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alkermes Plc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alkermes Plc to buy it.
The correlation of Alkermes Plc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alkermes Plc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alkermes Plc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alkermes Plc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alkermes Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Alkermes Stock please use our How to Invest in Alkermes Plc guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Alkermes Stock analysis
When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Alkermes Plc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alkermes Plc. If investors know Alkermes will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alkermes Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 3.06 | Revenue Per Share 10.007 | Quarterly Revenue Growth 0.239 | Return On Assets 0.1281 | Return On Equity 0.4622 |
The market value of Alkermes Plc is measured differently than its book value, which is the value of Alkermes that is recorded on the company's balance sheet. Investors also form their own opinion of Alkermes Plc's value that differs from its market value or its book value, called intrinsic value, which is Alkermes Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alkermes Plc's market value can be influenced by many factors that don't directly affect Alkermes Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alkermes Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alkermes Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alkermes Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.